Index
1 Market Overview of Homozygous Familial Hypercholesterolemia Epidemiology
1.1 Homozygous Familial Hypercholesterolemia Epidemiology Market Overview
1.1.1 Homozygous Familial Hypercholesterolemia Epidemiology Product Scope
1.1.2 Homozygous Familial Hypercholesterolemia Epidemiology Market Status and Outlook
1.2 Global Homozygous Familial Hypercholesterolemia Epidemiology Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Homozygous Familial Hypercholesterolemia Epidemiology Market Size by Region (2018-2029)
1.4 Global Homozygous Familial Hypercholesterolemia Epidemiology Historic Market Size by Region (2018-2023)
1.5 Global Homozygous Familial Hypercholesterolemia Epidemiology Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Homozygous Familial Hypercholesterolemia Epidemiology Market Size (2018-2029)
1.6.1 North America Homozygous Familial Hypercholesterolemia Epidemiology Market Size (2018-2029)
1.6.2 Europe Homozygous Familial Hypercholesterolemia Epidemiology Market Size (2018-2029)
1.6.3 Asia-Pacific Homozygous Familial Hypercholesterolemia Epidemiology Market Size (2018-2029)
1.6.4 Latin America Homozygous Familial Hypercholesterolemia Epidemiology Market Size (2018-2029)
1.6.5 Middle East & Africa Homozygous Familial Hypercholesterolemia Epidemiology Market Size (2018-2029)
2 Homozygous Familial Hypercholesterolemia Epidemiology Market by Type
2.1 Introduction
2.1.1 Statins
2.1.2 MTP inhibitors (Lomitapide)
2.1.3 PCSK9 inhibitors
2.1.4 Other
2.2 Global Homozygous Familial Hypercholesterolemia Epidemiology Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Homozygous Familial Hypercholesterolemia Epidemiology Historic Market Size by Type (2018-2023)
2.2.2 Global Homozygous Familial Hypercholesterolemia Epidemiology Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Homozygous Familial Hypercholesterolemia Epidemiology Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Homozygous Familial Hypercholesterolemia Epidemiology Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Homozygous Familial Hypercholesterolemia Epidemiology Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Homozygous Familial Hypercholesterolemia Epidemiology Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Homozygous Familial Hypercholesterolemia Epidemiology Revenue Breakdown by Type (2018-2029)
3 Homozygous Familial Hypercholesterolemia Epidemiology Market Overview by Application
3.1 Introduction
3.1.1 Hospital
3.1.2 Research Institute
3.1.3 Commercial
3.1.4 Other
3.2 Global Homozygous Familial Hypercholesterolemia Epidemiology Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Homozygous Familial Hypercholesterolemia Epidemiology Historic Market Size by Application (2018-2023)
3.2.2 Global Homozygous Familial Hypercholesterolemia Epidemiology Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Homozygous Familial Hypercholesterolemia Epidemiology Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Homozygous Familial Hypercholesterolemia Epidemiology Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Homozygous Familial Hypercholesterolemia Epidemiology Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Homozygous Familial Hypercholesterolemia Epidemiology Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Homozygous Familial Hypercholesterolemia Epidemiology Revenue Breakdown by Application (2018-2029)
4 Homozygous Familial Hypercholesterolemia Epidemiology Competition Analysis by Players
4.1 Global Homozygous Familial Hypercholesterolemia Epidemiology Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Homozygous Familial Hypercholesterolemia Epidemiology as of 2022)
4.3 Date of Key Players Enter into Homozygous Familial Hypercholesterolemia Epidemiology Market
4.4 Global Top Players Homozygous Familial Hypercholesterolemia Epidemiology Headquarters and Area Served
4.5 Key Players Homozygous Familial Hypercholesterolemia Epidemiology Product Solution and Service
4.6 Competitive Status
4.6.1 Homozygous Familial Hypercholesterolemia Epidemiology Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Regeneron Pharmaceuticals
5.1.1 Regeneron Pharmaceuticals Profile
5.1.2 Regeneron Pharmaceuticals Main Business
5.1.3 Regeneron Pharmaceuticals Homozygous Familial Hypercholesterolemia Epidemiology Products, Services and Solutions
5.1.4 Regeneron Pharmaceuticals Homozygous Familial Hypercholesterolemia Epidemiology Revenue (US$ Million) & (2018-2023)
5.1.5 Regeneron Pharmaceuticals Recent Developments
5.2 Novartis
5.2.1 Novartis Profile
5.2.2 Novartis Main Business
5.2.3 Novartis Homozygous Familial Hypercholesterolemia Epidemiology Products, Services and Solutions
5.2.4 Novartis Homozygous Familial Hypercholesterolemia Epidemiology Revenue (US$ Million) & (2018-2023)
5.2.5 Novartis Recent Developments
5.3 LIB Therapeutics
5.3.1 LIB Therapeutics Profile
5.3.2 LIB Therapeutics Main Business
5.3.3 LIB Therapeutics Homozygous Familial Hypercholesterolemia Epidemiology Products, Services and Solutions
5.3.4 LIB Therapeutics Homozygous Familial Hypercholesterolemia Epidemiology Revenue (US$ Million) & (2018-2023)
5.3.5 NeuroBo Pharmaceuticals Recent Developments
5.4 NeuroBo Pharmaceuticals
5.4.1 NeuroBo Pharmaceuticals Profile
5.4.2 NeuroBo Pharmaceuticals Main Business
5.4.3 NeuroBo Pharmaceuticals Homozygous Familial Hypercholesterolemia Epidemiology Products, Services and Solutions
5.4.4 NeuroBo Pharmaceuticals Homozygous Familial Hypercholesterolemia Epidemiology Revenue (US$ Million) & (2018-2023)
5.4.5 NeuroBo Pharmaceuticals Recent Developments
5.5 Arrowhead Pharmaceuticals
5.5.1 Arrowhead Pharmaceuticals Profile
5.5.2 Arrowhead Pharmaceuticals Main Business
5.5.3 Arrowhead Pharmaceuticals Homozygous Familial Hypercholesterolemia Epidemiology Products, Services and Solutions
5.5.4 Arrowhead Pharmaceuticals Homozygous Familial Hypercholesterolemia Epidemiology Revenue (US$ Million) & (2018-2023)
5.5.5 Arrowhead Pharmaceuticals Recent Developments
5.6 Amgen
5.6.1 Amgen Profile
5.6.2 Amgen Main Business
5.6.3 Amgen Homozygous Familial Hypercholesterolemia Epidemiology Products, Services and Solutions
5.6.4 Amgen Homozygous Familial Hypercholesterolemia Epidemiology Revenue (US$ Million) & (2018-2023)
5.6.5 Amgen Recent Developments
5.7 Aegerion Pharmaceutical
5.7.1 Aegerion Pharmaceutical Profile
5.7.2 Aegerion Pharmaceutical Main Business
5.7.3 Aegerion Pharmaceutical Homozygous Familial Hypercholesterolemia Epidemiology Products, Services and Solutions
5.7.4 Aegerion Pharmaceutical Homozygous Familial Hypercholesterolemia Epidemiology Revenue (US$ Million) & (2018-2023)
5.7.5 Aegerion Pharmaceutical Recent Developments
6 North America
6.1 North America Homozygous Familial Hypercholesterolemia Epidemiology Market Size by Country (2018-2029)
6.2 United States
6.3 Canada
7 Europe
7.1 Europe Homozygous Familial Hypercholesterolemia Epidemiology Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Homozygous Familial Hypercholesterolemia Epidemiology Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Homozygous Familial Hypercholesterolemia Epidemiology Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Homozygous Familial Hypercholesterolemia Epidemiology Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Homozygous Familial Hypercholesterolemia Epidemiology Market Dynamics
11.1 Homozygous Familial Hypercholesterolemia Epidemiology Industry Trends
11.2 Homozygous Familial Hypercholesterolemia Epidemiology Market Drivers
11.3 Homozygous Familial Hypercholesterolemia Epidemiology Market Challenges
11.4 Homozygous Familial Hypercholesterolemia Epidemiology Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List